Pimavanserin and Parkinson’s Disease Psychosis: A Narrative Review

Pimavanserin (PMV) is the first approved drug for treating hallucinations and delusions in Parkinson’s disease (PD) psychosis. Psychosis is one of the leading causes of nursing home placement in people with PD. Furthermore, hallucinations are a more frequent cause of institutionalization than motor...

Descripción completa

Detalles Bibliográficos
Autores principales: Rissardo, Jamir Pitton, Durante, Ícaro, Sharon, Idan, Fornari Caprara, Ana Letícia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9599742/
https://www.ncbi.nlm.nih.gov/pubmed/36291220
http://dx.doi.org/10.3390/brainsci12101286

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9599742/
https://www.ncbi.nlm.nih.gov/pubmed/36291220
http://dx.doi.org/10.3390/brainsci12101286

Ejemplares similares